Sprint Bioscience AB

Research Sprint Bioscience AB (SPRINT) on Bullrun: valuation model: 70.2% undervalued, market cap SEK 437.89M, P/E 4.4. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerSPRINT
• ExchangeST
• CountrySweden
• SectorHealthcare
• IndustryBiotechnology
• CurrencySEK
• Valuation signal70.2% undervalued
• Market capSEK 437.89M
• P/E4.4
• Financial periodQ4 2025
• RevenueSEK 133.91M
• Net incomeSEK 113.17M
• Free cash flowSEK 115.78M
• Gross margin99.2%

Valuation Snapshot

Bullrun's latest valuation model marks Sprint Bioscience AB as 70.2% undervalued; latest market cap is SEK 437.89M; P/E is 4.4.

About Sprint Bioscience AB

Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of drug candidates to treat cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; DCPS which is in preclinical trial for the treatment of acute myeloid leukemia; VRK1, which is in preclinical development to treat solid tumors; VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies;

Frequently asked questions

Is Sprint Bioscience AB overvalued or undervalued?

Bullrun's valuation model currently marks Sprint Bioscience AB as 70.2% undervalued.

What is Sprint Bioscience AB's market cap?

Sprint Bioscience AB's market capitalization is SEK 437.89M.

What is Sprint Bioscience AB's P/E ratio?

Sprint Bioscience AB's price-to-earnings (P/E) ratio is 4.4.

What does Sprint Bioscience AB do?

Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of drug candidates to treat cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies;